All In Biotech

Drug Trial Radar · NCT07271667

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

A Phase 2 Study of Emavusertib in Combination With an Approved Bruton Tyrosine Kinase Inhibitor in Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Curis, Inc.Industry
Sponsor type
Industry
First posted
Dec 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.

Conditions

  • Chronic Lymphocytic Leukemia
  • B-cell Malignancies

Interventions

  • EmavusertibDrug

    Oral tablets

  • ZanubrutinibDrug

    Oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Undetectable Measurable Residual Disease (uMRD) RateTime frame: Up to approximately 23 months
  2. Cohort 2: Overall Response Rate (ORR)Time frame: Up to approximately 23 months

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Mt Sinai Comprehensive Cancer Center

    Miami Beach, Florida · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Summit Medical Group

    Florham Park, New Jersey · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Texas Oncology - Sammons Cancer Center

    Dallas, Texas · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Maggiore Della Carità

    Novara, Italy · Recruiting

  • Azienda Ospedale Università Padova

    Padova, Italy · Recruiting

  • MD Anderson Cancer Center Madrid

    Madrid, Spain · Recruiting

  • Hospital Universitario Fundación Jiménez Díaz - START MADRID

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.